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Abstract Type I inositol 1,4,5-trisphosphate receptors can be
phosphorylated by cAMP-dependent protein kinase (PKA) and
cGMP-dependent protein kinase (PKG). To de¢ne the site-spe-
ci¢city of these events we analyzed the phosphorylation of mu-
tant receptors expressed in intact cells. These studies showed
that S1588 and S1755, the serine residues within kinase consensus
sequences, are equally sensitive to PKA, that phosphorylation
events at these sites are independent of each other, and that
PKG predominantly phosphorylates S1588. These ¢ndings pro-
vide the basis for understanding the functional consequences of
type I inositol 1,4,5-trisphosphate receptor phosphorylation.
- 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
Type I, II and III inositol 1,4,5-trisphosphate (InsP3) recep-
tors are a family of proteins which form Ca2þ channels in
endoplasmic reticulum membranes and which govern Ca2þ
release from this organelle by opening in response to InsP3
and Ca2þ binding [1^3]. The type I InsP3 receptor is the most
widely expressed and most extensively studied of the family
[2^5], and in addition to its activation by InsP3 and Ca2þ,
several modes of regulation have been established [2], includ-
ing phosphorylation by cAMP-dependent protein kinase
(PKA) and cGMP-dependent protein kinase (PKG) [6^13].
These kinases have been reported to phosphorylate the recep-
tor at two serine residues, designated S1588 and S1755 in the
mouse type I receptor [4,5,7,11,13]. The position of these sites,
between the ligand-binding domain and the channel domain
of the receptor [2,3,14,15], suggested that their phosphoryla-
tion might be involved in channel regulation. This was later
con¢rmed by ¢ndings that PKA-dependent phosphorylation
enhanced InsP3-induced Ca2þ mobilization [10,12,16^19].
Despite this knowledge, information on how S1588 and S1755
contribute to overall receptor phosphorylation is incomplete
and often contradictory. For example, early in vitro studies on
puri¢ed cerebellar type I InsP3 receptors demonstrating that
S1588 and S1755 were phosphorylated by PKA also indicated
that S1755 was considerably more susceptible to phosphoryla-
tion than S1588 [7], but as yet, this has not been veri¢ed in
intact cells. Further, PKG was shown to phosphorylate puri-
¢ed cerebellar receptor only at S1755 [11], but this was later
contradicted by ¢ndings from intact cells indicating that S1588
was the predominant site [13]. In order to clarify this situation
we have, for the ¢rst time, used a mutagenic approach to
characterize phosphorylation of the type I InsP3 receptor,
allowing us to directly measure and compare phosphorylation
at S1588 and S1755 in intact cells.
2. Materials and methods
2.1. Materials
Okadaic acid and sodium £uoride were from Alexis Corp, 32Pi
(H3PO4, carrier free) and [3H]InsP3 (23 Ci/mmol) were from Perkin
Elmer (NEN), [Q-32P]ATP (4500 Ci/mmol) was from ICN Biomedi-
cals, and PKA catalytic subunit was from Promega. All other chem-
icals were from Sigma.
2.2. Mutagenesis and transfection
Mutation of S1588 and S1755 to alanine in the SIþ/SIIþ (neuronal)
form of the mouse type I InsP3 receptor [4] was achieved as described
[20]. Brie£y, cDNA encoding mouse type I InsP3 receptor [21] was
mutagenized using the QuikChange kit (Stratagene) and pairs of mu-
tagenic primers [19]. The SacII/SbfI fragments containing the mutated
sites were then transferred into the correspondingly cut pcWI [21] and
correct introduction of the desired mutations was con¢rmed by cDNA
sequencing. Human embryonic kidney (HEK) cells, grown in mono-
layer as described [22], were seeded (750 000 cells/9.6 cm2 well) and
were transfected 24 h later with V1 Wg InsP3 receptor cDNA (or
empty vector) and 6 Wl Superfect (Qiagen) [20] and were used in
experiments 18^20 h later.
2.3. Phosphorylation of puri¢ed InsP3 receptors
Transfected cells were solubilized with 1 ml ice-cold lysis bu¡er [12]
supplemented with the phosphatase inhibitors Na3VO4 (1 mM), NaF
(100 mM) and okadaic acid (100 nM), and type I InsP3 receptors were
immunoprecipitated at 4‡C with type I InsP3 receptor-speci¢c CT1
[22] for 2 h and protein A-Sepharose CL-4B beads for 1 h. In vitro
phosphorylation of the puri¢ed receptors was then performed in 400
Wl phosphorylation bu¡er [12] supplemented with V20 WCi [Q-32P]
ATP, 5 WM non-radioactive ATP, and 40 units of PKA catalytic
subunit for 15 min at 30‡C. The immune complexes were then washed
three times with phosphorylation bu¡er supplemented with 1 mM
ATP and ¢nally resuspended in 2U gel loading bu¡er [22].
2.4. Phosphorylation of InsP3 receptors in intact cells
Wells of transfected HEK cells were incubated withV100 WCi 32Pi
for 2 h in 750 Wl serum-free, phosphate-free Dulbecco’s modi¢ed
Eagle’s medium and then stimulated to induce InsP3 receptor phos-
phorylation. Cells were then solubilized with inhibitor-supplemented
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lysis bu¡er, type I InsP3 receptors were immunoprecipitated, immune
complexes were washed three times with the same bu¡er and resus-
pended in 2U gel loading bu¡er. Alternatively, in a ‘back-phosphor-
ylation’ procedure [12], non-labeled transfected cells were incubated
with or without forskolin in 750 Wl serum-free Dulbecco’s modi¢ed
Eagle’s medium, and were then solubilized, and type I InsP3 receptors
were immunoprecipitated and phosphorylated with [Q-32P]ATP in vi-
tro.
2.5. Electrophoresis, staining, and autoradiography
Type I InsP3 receptors (V260 kDa) were electrophoresed in 5%
gels as described [22]. Gels were then stained with Coomassie blue
and radioactivity associated with electrophoresed InsP3 receptors was
assessed initially by autoradiography of dried gels and then quanti¢ed
by excision and scintillation counting of the V240^270 kDa region.
Phosphorylation stoichiometry was determined as described [12].
Brie£y, the number of moles of phosphate incorporated into InsP3
receptor was calculated from receptor radioactivity and [Q-32P]ATP
speci¢c activity, and the number of moles of InsP3 receptor was cal-
culated by measuring the number of [3H]InsP3 binding sites in recep-
tor preparations destined for phosphorylation.
2.6. [3H]InsP3 binding
Transfected HEK cells were harvested and homogenized [22], cen-
trifuged (16 000Ug for 10 min at 4‡C), resuspended in ice-cold 25 mM
Tris, 1 mM EDTA, pH 8.0, and were incubated at 4‡C with 1.3 nM
[3H]InsP3 for 20 min. Bound and free ligand were separated by ¢ltra-
tion through Whatman GF/B ¢lters and speci¢c binding was de¢ned
using 10 WM non-radiolabeled InsP3.
3. Results and discussion
3.1. S1588 and S1755 contribute equally to InsP3 receptor
phosphorylation following maximal PKA activation in
intact cells
We ¢rst examined phosphorylation in response to 10 WM
forskolin, a condition that causes maximal activation of ade-
nylyl cyclase and PKA in HEK cells [23]. Treatment of HEK
cells expressing exogenous wild-type type I InsP3 receptor
(InsP3RSS) with forskolin for 5 min (su⁄cient time for max-
imal phosphorylation; data not shown) caused an approxi-
mately four-fold increase in receptor phosphorylation over
basal levels (Fig. 1A, lanes 3 and 4). The signals obtained
(lanes 3 and 4) were dramatically greater than those seen in
vector-transfected cells (lanes 1 and 2), consistent with the
paucity of type I receptors in HEK cells [22], and indicating
that exogenous receptors account for essentially all of the
signal obtained from InsP3 receptor-transfected cells. Muta-
tion of both S1588 and S1755 to alanine (InsP3RAA) greatly
reduced basal phosphorylation and abolished forskolin-in-
duced phosphorylation (lanes 5 and 6), while mutation of
S1588 (InsP3RAS) or S1755 (InsP3RSA) reduced both basal and
forskolin-induced phosphorylation by V50% (lanes 7^10).
Erroneous expression of the mutant receptors did not account
for this reduction, as both InsP3RSS and InsP3RAA bound
InsP3 identically (Fig. 1B) and were similarly localized, as
indicated by immuno£uorescence microscopy (data not
shown). Thus, S1588 and S1755 contribute equally to type I
receptor phosphorylation under both resting conditions and
during maximal stimulation and are the only sites phosphor-
ylated by PKA; a third potential site (S2556) [4,5] within the
consensus sequence RKPS is clearly not a valid site for PKA.
3.2. Phosphorylation of puri¢ed receptors
We next sought to determine the stoichiometry of the phos-
phorylation seen in Fig. 1A, since only if a large proportion of
the exogenous receptors were e⁄ciently phosphorylated,
would our conclusions be valid. Puri¢ed InsP3RSS from un-
stimulated cells was phosphorylated by PKA in vitro with a
stoichiometry of 0.74 S 0.13 mol 32P/mol InsP3 receptor (Fig.
2A, lane 3; n=4), and this was reduced V90% by pretreat-
ment of intact cells with forskolin (lane 4). Thus, forskolin
appears to cause the incorporation of V0.7 mol phosphate/
mol InsP3 receptor in intact cells. However, since V25% of
exogenous receptors are already phosphorylated under basal
conditions (Fig. 1A, lane 3), this value is an underestimate of
the true stoichiometry. Furthermore, and surprisingly, analy-
sis of the phosphorylation of puri¢ed receptors showed that
S1755 (Fig. 2B, lane 4) was phosphorylated much less well than
S1588 (lane 5). Since the two sites are phosphorylated equally
well in intact cells (Fig. 1A), it appears that receptor immu-
nopuri¢cation suppresses S1755 phosphorylation, perhaps due
to distortion of the linker region between the channel-forming
and cytoplasmic domains of the receptor in which S1755 is
thought to reside [14], or due to the loss of required proteins.
These factors are likely to explain why our estimate and many
previous estimates [6,10^13] of type I receptor stoichiometry
are less than the 2 mol 32P/mol InsP3 receptor one would
expect if both S1588 and S1755 were phosphorylated e⁄ciently.
In view of these factors, we conclude that InsP3RSS is phos-
phorylated with a stoichiometry of at least 1 mol phosphate/
mol InsP3 receptor in intact cells. Thus, exogenous InsP3 re-
Fig. 1. Phosphorylation of exogenous type I InsP3 receptors in in-
tact HEK cells. A: 32Pi-labeled cells transfected with empty vector
(lanes 1 and 2) or InsP3 receptor cDNAs (lanes 3^10) were exposed
to 10 WM forskolin for 5 min as indicated and type I InsP3 recep-
tors were immunoprecipitated, electrophoresed and assessed for
staining capacity (upper panel) and associated radioactivity (lower
panel). The V200^300 kDa region of a gel is shown. Exogenous
InsP3 receptor phosphorylation (histogram, meanSS.E.M., n=3)
was calculated by subtracting radioactivity associated with endoge-
nous receptor (lane 1 or 2) from that in lanes 3^10 and is expressed
as a percentage of the radioactivity associated with InsP3RSS in the
presence of forskolin (lane 4). B: Speci¢c [3H]InsP3 binding to
membranes prepared from cells expressing exogenous receptor as in
A (meanSS.E.M., n=3).
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ceptor phosphorylation in intact cells (Fig. 1A) re£ects mod-
i¢cation of the majority of the receptors, rather than an in-
signi¢cant fraction.
3.3. Phosphorylation of S1588 and S1755 at submaximal
PKA activation in intact cells
We next sought to determine whether S1755 is preferentially
phosphorylated at submaximal PKA activation, as was con-
cluded from previous work in vitro [7]. For this study, we
examined phosphorylation in response to prostaglandin E1
(PGE1), which activates adenylyl cylclase through an endog-
enous G protein-coupled receptor [23], and produces more
moderate increases in cAMP levels than forskolin [24]. Fig.
3 shows that InsP3RAS and InsP3RSA were phosphorylated in
response to PGE1 with identical kinetics (A) and dose depen-
dence (B), and that at all times and PGE1 concentrations, the
mutants were phosphorylated toV50% of the level seen with
InsP3RSS. Thus, in contrast to previous results [7], these data
indicate that S1588 and S1755 are equally sensitive to PKA.
Furthermore, that InsP3RAS and InsP3RSA were phosphory-
lated equally well and addition of their phosphorylation sig-
nals equaled that seen with InsP3RSS (Figs. 1A and 3) indi-
cates that the two sites are non-interacting; phosphorylation
at position 1755 is una¡ected by events at position 1588, and
vice versa.
3.4. E¡ects of protein kinase C (PKC) and PKG activation on
InsP3 receptor phosphorylation in intact cells
Finally, we sought to de¢ne the e¡ects of PKC and PKG.
Activation of PKC, and the subsequent phosphorylation of
cellular substrates (Fig. 4A, lanes 3 and 4), with 1 WM phor-
bol-12-myristate 13-acetate (PMA) did not cause phosphory-
lation of InsP3RSS (Fig. 4A, lanes 1 and 2), indicating that, in
intact cells, the type I receptor is not a substrate for PKC.
Previous results showing PKC-dependent phosphorylation of
puri¢ed type I receptors in vitro [8], therefore, appear to re-
£ect a non-physiological process. Activation of PKG with 8-
Br-cGMP (Fig. 4B) resulted in a modest increase in InsP3RSS
phosphorylation, V30% of that seen in response to PKA
activation with 8-Br-cAMP. PKG-mediated phosphorylation
was almost exclusively on S1588, as InsP3RSA was phosphory-
lated equivalently to InsP3RSS, and much more than
InsP3RAS. The e¡ects of 8-Br-cGMP were not due to cross-
activation of PKA, as PKA activation led to phosphorylation
of both InsP3RAS and InsP3RSA (Fig. 4B). Thus, in intact
cells, PKG phosphorylates the type I InsP3 receptor predom-
inately at S1588.
4. Summary and conclusions
Analysis of exogenous InsP3RSS and its mutants in intact
cells has revealed that S1588 and S1755 are equally sensitive to
PKA, that phosphorylation at S1588 and phosphorylation at
S1755 are independent events, that PKG predominantly phos-
Fig. 2. Phosphorylation of puri¢ed type I InsP3 receptors. A: Cells
transfected with empty vector (lanes 1 and 2) or InsP3RSS cDNA
(lanes 3 and 4) were exposed to 10 WM forskolin for 5 min as indi-
cated, type I InsP3 receptors were immunoprecipitated and phos-
phorylated in vitro, and the stoichiometry of phosphorylation was
calculated. B: Type I InsP3 receptors were immunoprecipitated from
non-stimulated transfected cells and were phosphorylated in vitro.
Exogenous InsP3 receptor phosphorylation was calculated by sub-
tracting radioactivity incorporated into endogenous receptor (lane 1)
and expressed as a percentage of that seen with InsP3RSS. Data
shown are meanSS.E.M., n=4.
Fig. 3. PGE1-induced phosphorylation of S1588 and S1755. 32Pi-la-
beled cells transfected with cDNAs encoding InsP3RSS (F), In-
sP3RAS (b) or InsP3RSA (S) were exposed to PGE1 as indicated.
Exogenous InsP3 receptor phosphorylation was calculated as in
Fig. 1 (meanSS.E.M., n=3). A: Time course of phosphorylation.
B: Dose dependence of phosphorylation after 5 min incubations.
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phorylates S1588, and that PKC does not phosphorylate the
type I receptor. Overall, these ¢ndings disagree with the ma-
jority of in vitro studies on puri¢ed receptors using PKA and
PKG, in which preferential phosphorylation at S1755 has most
often been observed [7,11,13], and with ¢ndings that PKC
phosphorylates the type I receptor [8]. These discrepancies
may re£ect disruption of InsP3 receptors during puri¢cation
and/or the loss of associated proteins, and indicates that ex-
trapolation of results from in vitro studies to intact cells may
be invalid. In contrast, our data broadly agree with the only
study in which phosphorylation of S1588 and S1755 has been
mapped in intact cells; Haug et al. [13] found PKA-dependent
phosphorylation at both S1588 and S1755 (with some preference
for S1755) and PKG-dependent phosphorylation predomi-
nantly at S1588. Thus, exogenous receptors in HEK cells are
phosphorylated similarly to endogenous receptors, indicating
for the ¢rst time that analyses of the functional consequences
of phosphorylation of exogenously expressed receptors will
yield physiologically relevant data. In this regard, a recent
study in chicken DT40 cells expressing exogenous wild-type
SIIþ type I receptor showed that activation of both PKA and
PKG enhanced InsP3 receptor-mediated Ca2þ mobilization
and, based on studies with mutant receptors, that this resulted
from phosphorylation at S1755 [19] ; however, receptor phos-
phorylation was not assessed directly [19]. Thus, our data
broadly agree with these ¢ndings in that we demonstrate
phosphorylation of exogenously expressed type I InsP3 recep-
tors by both PKA and PKG. Paradoxically, however, while
the studies in DT40 cells suggest that PKG phosphorylates
S1755 [19], our data demonstrate that PKG phosphorylates
the type I receptor only at S1588 (Fig. 4B). Reconciliation of
this paradox may be attained when phosphorylation is mea-
sured in DT40 cells and, indeed, it is plausible that the site-
speci¢city of type I InsP3 receptor phosphorylation di¡ers
between cells types. This could re£ect di¡erential expression
of proteins that associate with the type I receptor, e.g. phos-
phatases [16,17].
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Fig. 4. E¡ects of PKC and PKG activation. 32Pi-labeled cells trans-
fected with InsP3 receptor cDNAs were exposed to 1 WM PMA,
1 mM 8-Br-cAMP or 8-Br-cGMP for 30 min as indicated and type
I InsP3 receptors were immunoprecipitated, electrophoresed and as-
sessed for associated radioactivity. A: Lanes 1 and 2 show an auto-
radiograph of immunoprecipitated InsP3RSS. Lanes 3 and 4 show
lysates from unstimulated or PMA-treated cells electrophoresed in
12% gels and probed in immunoblots with an antibody against
phospho-serine/threonine (#9621; Cell Signaling Technology) to
demonstrate that PKC was activated by PMA. The V65^150 kDa
region of a gel is shown. Data shown are representative of three in-
dependent experiments. B: Stimulated exogenous InsP3 receptor
phosphorylation was calculated by subtracting basal (unstimulated)
phosphorylation from stimulated levels for each receptor and is ex-
pressed as a percentage of the radioactivity associated with
InsP3RSS in response to 8-Br-cAMP. Data shown are meanS
S.E.M., n=3.
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